Enzymotec

Lipid-based Biofunctional Ingredients and Products

Health Tech & Life Sciences
Acquired (Inactive) by Frutarom on Jan 2018 - closed due to acquisition

Company Overview

Snapshot

Founded in March 1998, Enzymotec operates with 51–200 employees. The company raised a total of $100.4M across 6 funding rounds from 8 investors. In January 2018, Enzymotec was acquired by Frutarom, leading to its delisting from NASDAQ.

Business overview

Enzymotec is a biotechnology company specializing in the development and production of biofunctional ingredients derived from lipids. These ingredients are designed to address diverse health needs, ranging from infant nutrition to senior citizen care. The company's nutrition segment provides lipid-based ingredients for products such as infant formula and dietary supplements, while its VAYA pharmaceutical segment focuses on branded lipid-based medical foods for managing cardiovascular and neurological disorders. Enzymotec operates within the Health Tech & Life Sciences sector, with a focus on pharmaceuticals and biomaterials.

Strategic signal

In January 2018, Aker BioMarine acquired Enzymotec's krill oil business, coinciding with Frutarom's completion of its main takeover of Enzymotec. This strategic divestiture and acquisition highlight the specialized value of Enzymotec's product lines and the consolidation within the biofunctional ingredients market, indicating a shift in ownership and strategic focus for the company's assets.

Company Intelligence Q&A

What was a significant exit event for Enzymotec?
Enzymotec was acquired by Frutarom in January 2018, leading to its delisting from NASDAQ.
Which company acquired Enzymotec's krill oil business?
Aker BioMarine acquired Enzymotec's krill oil business in January 2018, as Frutarom completed its main takeover of Enzymotec.
When did Enzymotec go public?
Enzymotec completed an Initial Public Offering (IPO) on NASDAQ in September 2013.
Which investors participated in Enzymotec's B Round in February 2009?
In February 2009, Enzymotec received funding in a B Round from investors including Ofer Hi-Tech.
Which investors participated in Enzymotec's funding round in June 2001?
In June 2001, Enzymotec received funding from investors including Galam and MMT Funds.

External links